Page last updated: 2024-12-07

mafosfamide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

mafosfamide: RN given refers to cis-(+-)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID104746
CHEMBL ID59990
SCHEMBL ID1652310
MeSH IDM0139148

Synonyms (15)

Synonym
mafosfamide
88859-04-5
CHEMBL59990
84211-05-2
mafosfamide sodium salt
AKOS015909832
PBUUPFTVAPUWDE-UHFFFAOYSA-N
2-[2-(bis-(2-chloroethyl)-amino)-2-oxo-tetrahydro-2h-1,3,2-oxazaphosphorin-4-yl-thio]-ethanesulphonic acid
2-[2-(bis-(2 chloroethyl)-amino)-2-oxo-tetrahydro-2h-1,3,2-oxazaphosphorin-4-yl-thio]-ethanesulphonic acid
SCHEMBL1652310
z 7557;z-7557;z7557;cis-mafosfamide;mafosfamid
6-aminocoumarinhydrochloride
2-[[2-[bis(2-chloroethyl)amino]-2-oxo-1,3,2lambda5-oxazaphosphinan-4-yl]sulfanyl]ethanesulfonic acid
2-({2-[bis(2-chloroethyl)amino]-2-oxo-1,3,2lambda~5~-oxazaphosphinan-4-yl}sulfanyl)ethane-1-sulfonic acid
DTXSID40869012

Research Excerpts

Overview

Mafosfamide (ASTA-Z 7557) is a chemotherapeutic agent currently used for purging human bone marrow cells prior to autologous bone marrow transplantation. It is a cyclophosphamide derivative, which does not require hepatic activation and thus can be utilized for regional therapy.

ExcerptReferenceRelevance
"Mafosfamide (ASTA-Z) is a chemotherapeutic agent currently in use for in vitro purging of tumor-bearing human BM cells prior to autologous bone marrow transplantation (ABMT). "( Successful purging of murine plasmacytoma by mafosfamide (ASTA-Z).
Reich, S; Sidi, H; Slavin, G; Slavin, S; Weiss, L, 1994
)
1.99
"Mafosfamide, which is a cyclophosphamide derivative that rapidly generates 4-Hydroperoxycyclophosphamide after aqueous dissolution, was employed in doses ranging from 0.1 to 20 micrograms/ml."( C-myc expression is down-regulated in mafosfamide-treated HL-60 cells undergoing apoptosis.
Davidoff, AN; Mendelow, BV,
)
1.12
"Mafosfamide (ASTA-Z 7557) is a chemotherapeutic agent currently used for purging human bone marrow cells prior to autologous bone marrow transplantation. "( ASTA-Z 7557 impairs human natural killer (NK) cell activity.
Condiotti, R; Nagler, A; Slavin, S, 1996
)
1.74
"Mafosfamide is a cyclophosphamide derivative, which does not require hepatic activation and thus can be utilized for regional therapy."( Intrathecal mafosfamide therapy for pediatric brain tumors with meningeal dissemination.
Czech, T; Dieckmann, K; Hainfellner, JA; Schuller, E; Seidl, R; Slavc, I,
)
1.23
"Mafosfamide (Mafo) is an analog of cyclophosphamide that does not require hepatic activation and therefore has in vitro activity. "( Enhancement of cytotoxic T lymphocyte growth from spleens of P815-tumor-bearing host mice with mafosfamide.
Bear, HD; Bethke, KP; Frank, JL; Hoover, SK; Inge, TH; Kawabata, TT, 1992
)
1.94

Treatment

Mafosfamide, fludarabine, and IL-4 resulted in significant anti-tumor activity against all the freshly isolated samples.

ExcerptReferenceRelevance
"to mafosfamide-treated animals was even more effective against its lethal toxicity (LD50 i.p."( Influence of mesna and cysteine on the systemic toxicity and therapeutic efficacy of activated cyclophosphamide.
Schwieder, G; Wagner, T; Zink, M, 1987
)
0.79
"in mafosfamide i.p. treatment is superior to mafosfamide i.p."( Intracavitary chemotherapy with activated cyclophosphamides and simultaneous systemic detoxification with protector thiols in Sarcoma 180 ascites tumor.
Mittendorff, F; Wagner, T; Walter, E, 1986
)
0.78
"Treatment with mafosfamide, fludarabine, and IL-4 resulted in significant anti-tumor activity against all the freshly isolated samples."( Induction of "in vitro" apoptosis by fludarabine in freshly isolated B-chronic lymphocytic leukemia cells.
Buzzi, M; Farabegoli, P; Fortuna, A; Martinelli, G; Tosi, P; Tura, S; Visani, G; Zaccaria, A; Zinzani, PL, 1994
)
0.63

Toxicity

ExcerptReferenceRelevance
" Mice bearing murine renal cancer (Renca) were also protected from the acute toxic effects of Cy (450 mg/kg) by pretreatment with rhIL-1 alpha."( Chemoprotective effects of recombinant human IL-1 alpha in cyclophosphamide-treated normal and tumor-bearing mice. Protection from acute toxicity, hematologic effects, development of late mortality, and enhanced therapeutic efficacy.
Futami, H; Jansen, R; Keller, J; Longo, DL; MacPhee, MJ; McCormick, K; Oppenheim, JJ; Ruscetti, FW; Wiltrout, RH, 1990
)
0.28
" The results of this study will show that amifostine protects normal late and early progenitor cells for the toxic effects of cyclophosphamide derivatives while preserving their antileukaemic effects."( Amifostine (WR-2721) protects normal haematopoietic stem cells against cyclophosphamide derivatives' toxicity without compromising their antileukaemic effects.
Douay, L; Giarratana, MC; Gorin, NC; Hu, C, 1995
)
0.29

Compound-Compound Interactions

Nilotinib in combination with mafosfamide, treosulfan, or busulfan resulted in synergistic ( CI < 1), additive (CI ~ 1), and predominantly antagonistic (CI > 1) effects.

ExcerptReferenceRelevance
"In an attempt to improve in vitro pharmacological purging of autologous grafts, the ability of doxorubicin (DOX), alone and in combination with mafosfamide (AZ), to eliminate tumor cells from human bone marrow was assessed."( Evaluation of doxorubicin in combination with mafosfamide for in vitro elimination of myeloid and lymphoid tumor cells from human bone marrow.
Binet, C; Brémond, JL; Chassaigne, M; Colombat, P; Domenech, J; Georget, MT; Gihana, E; Lamagnère, JP, 1992
)
0.74
" The type of interaction was different between patients, and depends on the drug combination and concentrations."( Drug combination testing in acute lymphoblastic leukemia using the MTT assay.
Hählen, K; Kaspers, GJ; Pieters, R; Van Wering, ER; Van Zantwijk, I; Veerman, AJ, 1995
)
0.29
" These results support that fludarabine in combination with cyclophosphamide and/or mitoxantrone can be highly effective in the treatment of B-CLL."( In vitro evaluation of fludarabine in combination with cyclophosphamide and/or mitoxantrone in B-cell chronic lymphocytic leukemia.
Bellosillo, B; Colomer, D; Gil, J; Montserrat, E; Pons, G; Villamor, N, 1999
)
0.3
"Cladribine (C) and fludarabine (F) combined with cyclophosphamide/mafosfamide in vivo, as well as ex vivo trigger apoptosis in CLL cells."( In vivo and ex vivo responses of CLL cells to purine analogs combined with alkylating agent.
Borowiak, A; Błoński, JZ; Cebula-Obrzut, B; Kiliańska, ZM; Kotkowska, A; Robak, T; Rogalińska, M; Smolewski, P; Wawrzyniak, E; Żołnierczyk, JD, 2013
)
0.63
" We therefore investigated the antiproliferative effects of nilotinib in combination with drugs that are usually used for conditioning: the alkylating agents mafosfamide, treosulfan, and busulfan."( In vitro testing of drug combinations employing nilotinib and alkylating agents with regard to pretransplant conditioning treatment of advanced-phase chronic myeloid leukemia.
Dreger, P; Fruehauf, S; Ho, AD; Jens Zeller, W; Luft, T; Radujkovic, A; Topaly, J, 2014
)
0.6
"Treatment of imatinib-sensitive, BCR-ABL-positive K562 and LAMA84 cells with nilotinib in combination with mafosfamide, treosulfan, or busulfan resulted in synergistic (CI < 1), additive (CI ~ 1), and predominantly antagonistic (CI > 1) effects, respectively."( In vitro testing of drug combinations employing nilotinib and alkylating agents with regard to pretransplant conditioning treatment of advanced-phase chronic myeloid leukemia.
Dreger, P; Fruehauf, S; Ho, AD; Jens Zeller, W; Luft, T; Radujkovic, A; Topaly, J, 2014
)
0.62

Dosage Studied

All drugs but mafosfamide, tested in place of cyclophosphamide, were used at concentrations corresponding to the in vivo dosage employed in the CEOP regimen. Dose-response relationship studies with cycloph phosphamide and its stabilized 4-hydroxy-derivative mafsfamide showed a bell-shaped pattern.

ExcerptRelevanceReference
" Dose-response relationship studies with cyclophosphamide and its stabilized 4-hydroxy-derivative mafosfamide showed a bell-shaped pattern."( Oxazaphosphorine effects in L 5222 rat leukemia.
Pohl, J; Reissmann, T; Voegeli, R, 1987
)
0.49
" All drugs but mafosfamide, tested in place of cyclophosphamide, were used at concentrations corresponding to the in vivo dosage employed in the CEOP regimen."( In vitro chemosensitivity of chronic lymphocytic leukemia B-cells to multidrug regimen (CEOP) compounds using the MTT colorimetric assay.
Brugiatelli, M; Callea, V; Messina, G; Morabito, F; Nobile, F; Oliva, B; Ramirez, F,
)
0.48
" A lethal dose 95 (LD95) was calculated from the dose-response curve."( Sensitivity of human CFU-GM to mafosfamide: analysis of the factors affecting individual variations.
Binet, C; Brémond, JL; Chenault, S; Colombat, P; Desbois, I; Domenech, J; Gihana, E; Lamagnère, JP; Linassier, C, 1993
)
0.57
" Melphalan was administered at a dosage of 150-220 mg/m(2) (median 180)."( High-dose melphalan with autologous hematopoietic stem cell transplantation for acute myeloid leukemia: results of a retrospective analysis of the Italian Pediatric Group for Bone Marrow Transplantation.
Bagnulo, S; Caniggia, M; Cesaro, S; Lanino, E; Locatelli, F; Meloni, G; Messina, C; Pession, A; Pillon, M; Proglia, A, 2001
)
0.31
" Therefore, a strategy to alternate dosing between the intralumbar and intraventricular routes was tested."( Intrathecal mafosfamide: a preclinical pharmacology and phase I trial.
Adamson, PC; Aikin, A; Arndt, CA; Balis, FM; Berg, S; Blaney, SM; Geyer, JR; Heideman, R; Jaeckle, K; Klenke, R; McCully, C; Murphy, R; Packer, R; Poplack, DG, 2005
)
0.71
" To obtain a better therapeutic index, a strategy to alternate dosing between the intraventricular and intralumbar routes is also being tested."( Mafosfamide as a new anticancer agent: preclinical investigations and clinical trials.
Mazur, L; Opydo-Chanek, M; Stojak, M; Wojcieszek, K, 2012
)
1.82
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (1)

Assay IDTitleYearJournalArticle
AID93938Concentration required to reduce the viability of L1210 cells by 50% after 1-h incubation at 37 degrees C1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Aldophosphamide acetal diacetate and structural analogues: synthesis and cytotoxicity studies.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (238)

TimeframeStudies, This Drug (%)All Drugs %
pre-199051 (21.43)18.7374
1990's134 (56.30)18.2507
2000's32 (13.45)29.6817
2010's19 (7.98)24.3611
2020's2 (0.84)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 22.33

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index22.33 (24.57)
Research Supply Index5.61 (2.92)
Research Growth Index4.61 (4.65)
Search Engine Demand Index26.67 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (22.33)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials24 (9.64%)5.53%
Reviews17 (6.83%)6.00%
Case Studies8 (3.21%)4.05%
Observational0 (0.00%)0.25%
Other200 (80.32%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (4)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Phase I Study of Intrathecal Mafosfamide [NCT00001251]Phase 165 participants Interventional1989-11-30Completed
Pilot Study of Systemic and Intrathecal Chemotherapy Followed by Conformal Radiation for Infants With Brain Tumors [NCT00042367]119 participants (Actual)Interventional2000-04-04Completed
Phase I Study of Intrathecal Mafosfamide [NCT00062881]Phase 165 participants Interventional1990-06-30Completed
Phase I Study of Intrathecal Mafosfamide [NCT00031928]Phase 13,000 participants (Anticipated)Interventional2002-01-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]